Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 1.00 |
| ▸ | CA9 | Q16790 | 4/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343758 | 0.92 | CA9 (1.00) | CHRNA7CA9PTGS2SMN1; SMN2CA1 | |
| SCHEMBL7627415 | 0.91 | CHRNA7 (0.83) | CHRNA7CA9PTGS2PTGS1 | |
| SCHEMBL6342008 | 0.90 | CHRNA7 (1.00) | CHRNA7CA9PTGS2SMN1; SMN2 | |
| SCHEMBL9941851 | 0.89 | CA9 (1.00) | CHRNA7CA9PTGS2SMN1; SMN2CA1 | |
| SCHEMBL6342214 | 0.88 | PTGS2 (1.00) | CHRNA7CA9PTGS2SMN1; SMN2PTGS1 | |
| SCHEMBL9206474 | 0.87 | CHRNA7 (0.77) | CHRNA7CA9PTGS2 | |
| SCHEMBL9203679 | 0.87 | CHRNA7 (0.77) | CHRNA7CA9PTGS2SMN1; SMN2PTGS1 | |
| SCHEMBL9212244 | 0.84 | CHRNA7 (0.72) | CHRNA7CA9PTGS2 | |
| SCHEMBL9203093 | 0.84 | CHRNA7 (0.72) | CHRNA7CA9PTGS2 | |
| SCHEMBL6344501 | 0.83 | PTGS2 (0.76) | CHRNA7CA9PTGS2SMN1; SMN2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2051966-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | Pfizer Products Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | CHRNA7 3165/4885CA9 3/4885PTGS2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.